Tomohito Kuwako
YOU?
Author Swipe
View article: Circulating Tumour <scp>DNA</scp> in Patients With <scp><i>EGFR</i></scp>‐Mutated Non‐Small‐Cell Lung Cancer and Early Disease Progression After First‐Line Osimertinib Treatment: The <scp>ELUCIDATOR</scp> Multicentre Prospective Observational Study
Circulating Tumour <span>DNA</span> in Patients With <span><i>EGFR</i></span>‐Mutated Non‐Small‐Cell Lung Cancer and Early Disease Progression After First‐Line Osimertinib Treatment: The <span>ELUCIDATOR</span> Multicentre Prospective Observational Study Open
Background Osimertinib is the standard therapy for patients with chemotherapy‐naive advanced non‐small‐cell lung cancer (NSCLC) harbouring sensitising epidermal growth factor receptor ( EGFR ) mutations. However, some patients treated with…
View article: Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status
Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status Open
There was no between-group difference in PFS, although OS was significantly inferior in the poor PS group. Additionally, there was a significant increase in APC-positive cases and a trend toward more CTNNB1-positive cases in the poor PS gr…
View article: Mechanisms of Resistance and Correlation between Pre-Treatment Co-Alterations and Prognosis to Osimertinib in Chemo-Naïve Advanced Non-Small Cell Lung Cancer
Mechanisms of Resistance and Correlation between Pre-Treatment Co-Alterations and Prognosis to Osimertinib in Chemo-Naïve Advanced Non-Small Cell Lung Cancer Open
View article: Supplementary Material for: Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer
Supplementary Material for: Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer Open
Introduction: Treatment outcomes in patients with advanced non-small cell lung cancer (NSCLC) are poor due to limited treatment options. Objective: We conducted a multicenter, single-arm phase II study to prospe…
View article: Predictors of Discontinuance of Oral Feeding in Patients With Advanced Alzheimer Dementia and Aspiration Pneumonia in Japan
Predictors of Discontinuance of Oral Feeding in Patients With Advanced Alzheimer Dementia and Aspiration Pneumonia in Japan Open
Background: Difficulty with oral feeding, the most commonly observed complication of Alzheimer disease (AD) in its final stages, occurs in 86% of AD patients and may prevent achievement of oral feeding after aspiration pneumonia. However, …
View article: The plasma ctDNA monitoring during epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)
The plasma ctDNA monitoring during epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial) Open
Background: Approximately 60% of EGFR mutant non-small cell lung cancer (NSCLC) patients treated with first/second generation EGFR-TKIs will acquire resistance by the T790M mutation. Since osimertinib, a third generation EGFR-TKI, is activ…
View article: Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer
Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer Open
View article: Hydroxyurea-induced Pneumonitis in a Patient with Chronic Myelomonocytic Leukemia: An Autopsy Case
Hydroxyurea-induced Pneumonitis in a Patient with Chronic Myelomonocytic Leukemia: An Autopsy Case Open
We describe the case of an 85-year-old man diagnosed with chronic myelomonocytic leukemia whose disease was treated with hydroxyurea for 3 months. He developed respiratory symptoms that were extensively investigated. Despite the intensive …